{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:10:46Z","timestamp":1791943846814,"version":"4.3.4"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11523-026-01249-6","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:26:16Z","timestamp":1786541176000},"page":"701-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rare Molecular Variants of Gastrointestinal Stromal Tumors (GISTs): Clinical Implications and Overview of Current Evidence"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8543-8768","authenticated-orcid":false,"given":"Anna","family":"Klimczak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8516-6971","authenticated-orcid":false,"given":"Katarzyna","family":"Kisielewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-3422","authenticated-orcid":false,"given":"Anna","family":"Szumera-Cie\u0107kiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-5429","authenticated-orcid":false,"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"6","key":"1249_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.5603\/OCP.2018.0053","volume":"14","author":"P Rutkowski","year":"2018","unstructured":"Rutkowski P, Szumera-Cie\u0107kiewicz A. Gastrointestinal stromal tumours (GIST): 2018. Oncol Clin Pract. 2018;14(6):399\u2013407. https:\/\/doi.org\/10.5603\/OCP.2018.0053.","journal-title":"Oncol Clin Pract"},{"key":"1249_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","volume":"40","author":"K S\u00f8reide","year":"2016","unstructured":"S\u00f8reide K, Sandvik OM, S\u00f8reide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39\u201346. https:\/\/doi.org\/10.1016\/j.canep.2015.10.031.","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"1249_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10120-025-01639-1","volume":"28","author":"K Kawabata","year":"2025","unstructured":"Kawabata K, Takahashi T, Nishida T, Kurokawa Y, Yamamoto K, Saito T, et al. Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors. Gastric Cancer. 2025;28(5):899\u2013910. https:\/\/doi.org\/10.1007\/s10120-025-01639-1.","journal-title":"Gastric Cancer"},{"issue":"7","key":"1249_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, Von Mehren M, Blanke CD, Van Den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472\u201380. https:\/\/doi.org\/10.1056\/NEJMoa020461.","journal-title":"N Engl J Med"},{"issue":"9863","key":"1249_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295\u2013302. https:\/\/doi.org\/10.1016\/S0140-6736(12)61857-1.","journal-title":"Lancet"},{"issue":"34","key":"1249_CR6","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.22.00294","volume":"40","author":"S Bauer","year":"2022","unstructured":"Bauer S, Jones RL, Blay JY, Gelderblom H, George S, Sch\u00f6ffski P, et al. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib (INTRIGUE): a randomized, open-label, phase III trial. J Clin Oncol. 2022;40(34):3918\u201328. https:\/\/doi.org\/10.1200\/JCO.22.00294.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1249_CR7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/modpathol.2008.2","volume":"21","author":"J Lasota","year":"2008","unstructured":"Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E, et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol. 2008;21(4):476\u201384. https:\/\/doi.org\/10.1038\/modpathol.2008.2.","journal-title":"Mod Pathol"},{"issue":"2","key":"1249_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","volume":"23","author":"M Miettinen","year":"2006","unstructured":"Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70\u201383. https:\/\/doi.org\/10.1053\/j.semdp.2006.09.001.","journal-title":"Semin Diagn Pathol"},{"issue":"8","key":"1249_CR9","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.3748\/wjg.v21.i8.2303","volume":"21","author":"YM Wang","year":"2015","unstructured":"Wang YM. Succinate dehydrogenase-deficient gastrointestinal stromal tumors. World J Gastroenterol. 2015;21(8):2303\u201314. https:\/\/doi.org\/10.3748\/wjg.v21.i8.2303.","journal-title":"World J Gastroenterol"},{"issue":"5350","key":"1249_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577\u201380. https:\/\/doi.org\/10.1126\/science.279.5350.577.","journal-title":"Science"},{"issue":"18","key":"1249_CR11","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1200\/JCO.2004.05.140","volume":"22","author":"CL Corless","year":"2004","unstructured":"Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22(18):3813\u201325. https:\/\/doi.org\/10.1200\/JCO.2004.05.140.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1249_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10555-019-09818-0","volume":"38","author":"P Neppala","year":"2019","unstructured":"Neppala P, Banerjee S, Fanta PT, Yerba M, Porras KA, Burgoyne AM, et al. Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors. Cancer Metastasis Rev. 2019;38(3):525\u201335. https:\/\/doi.org\/10.1007\/s10555-019-09818-0.","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"1249_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMc071191","volume":"357","author":"SR McWhinney","year":"2007","unstructured":"McWhinney SR, Pasini B, Stratakis CA. Familial gastrointestinal stromal tumors and germ-line mutations. N Engl J Med. 2007;357(10):1054\u20136. https:\/\/doi.org\/10.1056\/NEJMc071191.","journal-title":"N Engl J Med"},{"issue":"2","key":"1249_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/annonc\/mdr127","volume":"23","author":"A Wozniak","year":"2012","unstructured":"Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, et al. Prognostic value of KIT\/PDGFRA mutations in gastrointestinal stromal tumours (GIST): polish clinical GIST registry experience. Ann Oncol. 2012;23(2):353\u201360. https:\/\/doi.org\/10.1093\/annonc\/mdr127.","journal-title":"Ann Oncol"},{"issue":"1","key":"1249_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01411-x","volume":"22","author":"S Zhou","year":"2024","unstructured":"Zhou S, Abdihamid O, Tan F, Zhou H, Liu H, Li Z, et al. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST. Cell Commun Signal. 2024;22(1):153. https:\/\/doi.org\/10.1186\/s12964-023-01411-x.","journal-title":"Cell Commun Signal"},{"issue":"3","key":"1249_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.humpath.2013.10.025","volume":"45","author":"H K\u00fcnstlinger","year":"2014","unstructured":"K\u00fcnstlinger H, Binot E, Merkelbach-Bruse S, Huss S, Wardelmann E, Buettner R, et al. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors. Hum Pathol. 2014;45(3):573\u201382. https:\/\/doi.org\/10.1016\/j.humpath.2013.10.025.","journal-title":"Hum Pathol"},{"issue":"33","key":"1249_CR17","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352\u20139. https:\/\/doi.org\/10.1200\/JCO.2007.15.7461.","journal-title":"J Clin Oncol"},{"issue":"7317","key":"1249_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nature09409","volume":"467","author":"P Chi","year":"2010","unstructured":"Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 2010;467(7317):849\u201353. https:\/\/doi.org\/10.1038\/nature09409.","journal-title":"Nature"},{"issue":"3","key":"1249_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/2159-8290.CD-14-0985","volume":"5","author":"L Ran","year":"2015","unstructured":"Ran L, Sirota I, Cao Z, Murphy D, Chen Y, Shukla S, et al. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discov. 2015;5(3):304\u201315. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0985.","journal-title":"Cancer Discov"},{"issue":"22","key":"1249_CR20","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1038\/sj.onc.1207525","volume":"23","author":"A Duensing","year":"2004","unstructured":"Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004;23(22):3999\u20134006. https:\/\/doi.org\/10.1038\/sj.onc.1207525.","journal-title":"Oncogene"},{"issue":"40","key":"1249_CR21","doi-asserted-by":"publisher","first-page":"E8448","DOI":"10.1073\/pnas.1711449114","volume":"114","author":"B Bosbach","year":"2017","unstructured":"Bosbach B, Rossi F, Yozgat Y, Loo J, Zhang JQ, Berrozpe G, et al. Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor. Proc Natl Acad Sci U S A. 2017;114(40):E8448\u201357. https:\/\/doi.org\/10.1073\/pnas.1711449114.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"59","key":"1249_CR22","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.18632\/oncotarget.27277","volume":"10","author":"C Serrano","year":"2019","unstructured":"Serrano C, Fletcher JA. Overcoming heterogeneity in imatinib-resistant gastrointestinal stromal tumor. Oncotarget. 2019;10(59):6286\u20137. https:\/\/doi.org\/10.18632\/oncotarget.27277.","journal-title":"Oncotarget"},{"issue":"39","key":"1249_CR23","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.1038\/s41388-019-0894-3","volume":"38","author":"WB Ou","year":"2019","unstructured":"Ou WB, Ni N, Zuo R, Zhuang W, Zhu M, Kyriazoglou A, et al. Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Oncogene. 2019;38(39):6615\u201329. https:\/\/doi.org\/10.1038\/s41388-019-0894-3.","journal-title":"Oncogene"},{"key":"1249_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/tgh.2018.01.02","volume":"3","author":"T Niinuma","year":"2018","unstructured":"Niinuma T, Suzuki H, Sugai T. Molecular characterization and pathogenesis of gastrointestinal stromal tumor. Transl Gastroenterol Hepatol. 2018;3:2. https:\/\/doi.org\/10.21037\/tgh.2018.01.02.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"5","key":"1249_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051057","volume":"10","author":"V Indio","year":"2021","unstructured":"Indio V, Schipani A, Nannini M, Urbini M, Rizzo A, De Leo A, et al. Gene expression landscape of SDH-deficient gastrointestinal stromal tumors. J Clin Med. 2021;10(5):1057. https:\/\/doi.org\/10.3390\/jcm10051057.","journal-title":"J Clin Med"},{"key":"1249_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.730213","volume":"9","author":"C Yan","year":"2022","unstructured":"Yan C, Zhao C, Yang K, Zhou H, Jing L, Zhao W, et al. Rare C-KIT c.1926delA and c.1936T>G mutations in exon 13 define imatinib resistance in gastrointestinal stromal tumors and melanoma patients: case reports and cell experiments. Front Mol Biosci. 2022;9:730213. https:\/\/doi.org\/10.3389\/fmolb.2022.730213.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"1249_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/fon-2016-0192","volume":"13","author":"Z Szucs","year":"2017","unstructured":"Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017;13(1):93\u2013107. https:\/\/doi.org\/10.2217\/fon-2016-0192.","journal-title":"Future Oncol"},{"issue":"6","key":"1249_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41416-019-0388-7","volume":"120","author":"A Napolitano","year":"2019","unstructured":"Napolitano A, Vincenzi B. Secondary KIT mutations: the GIST of drug resistance and sensitivity. Br J Cancer. 2019;120(6):577\u20138. https:\/\/doi.org\/10.1038\/s41416-019-0388-7.","journal-title":"Br J Cancer"},{"issue":"5","key":"1249_CR29","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1073\/pnas.0812413106","volume":"106","author":"KS Gajiwala","year":"2009","unstructured":"Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA. 2009;106(5):1542\u20137. https:\/\/doi.org\/10.1073\/pnas.0812413106.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"33","key":"1249_CR30","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CDM, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26(33):5360\u20137. https:\/\/doi.org\/10.1200\/JCO.2008.17.4284.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1249_CR31","first-page":"8024","volume":"7","author":"T Ito","year":"2014","unstructured":"Ito T, Yamamura M, Hirai T, Ishikawa T, Kanda T, Nakai T, et al. Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature. Int J Clin Exp Pathol. 2014;7(11):8024\u201331.","journal-title":"Int J Clin Exp Pathol"},{"issue":"7","key":"1249_CR32","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/modpathol.2013.47","volume":"26","author":"S Huss","year":"2013","unstructured":"Huss S, K\u00fcnstlinger H, Wardelmann E, Kleine MA, Binot E, Merkelbach-Bruse S, et al. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). Mod Pathol. 2013;26(7):1004\u201312. https:\/\/doi.org\/10.1038\/modpathol.2013.47.","journal-title":"Mod Pathol"},{"issue":"23","key":"1249_CR33","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357\u201364. https:\/\/doi.org\/10.1200\/JCO.2005.14.068.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1249_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020194","volume":"11","author":"I Br\u010di\u0107","year":"2021","unstructured":"Br\u010di\u0107 I, Argyropoulos A, Liegl-Atzwanger B. Update on molecular genetics of gastrointestinal stromal tumors. Diagnostics (Basel). 2021;11(2):194. https:\/\/doi.org\/10.3390\/diagnostics11020194.","journal-title":"Diagnostics (Basel)"},{"key":"1249_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672500","volume":"11","author":"S Bauer","year":"2021","unstructured":"Bauer S, George S, Von Mehren M, Heinrich MC. Early and next-generation KIT\/PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor. Front Oncol. 2021;11:672500. https:\/\/doi.org\/10.3389\/fonc.2021.672500.","journal-title":"Front Oncol"},{"issue":"1","key":"1249_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-015-0036-9","volume":"5","author":"AS Brohl","year":"2015","unstructured":"Brohl AS, Demicco EG, Mourtzikos M, Maki RG. Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation. Clin Sarcoma Res. 2015;5(1):21. https:\/\/doi.org\/10.1186\/s13569-015-0036-9.","journal-title":"Clin Sarcoma Res"},{"issue":"1","key":"1249_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/labinvest.3700360","volume":"86","author":"J Lasota","year":"2006","unstructured":"Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest. 2006;86(1):94\u2013100. https:\/\/doi.org\/10.1038\/labinvest.3700360.","journal-title":"Lab Invest"},{"issue":"16","key":"1249_CR38","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1158\/1078-0432.CCR-11-3025","volume":"18","author":"PA Cassier","year":"2012","unstructured":"Cassier PA, Fumagalli E, Rutkowski P, Sch\u00f6ffski P, Van Glabbeke M, Debiec-Rychter M, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012;18(16):4458\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3025.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1249_CR39","doi-asserted-by":"publisher","first-page":"655","DOI":"10.5858\/arpa.2018-0370-RS","volume":"144","author":"A Ibrahim","year":"2020","unstructured":"Ibrahim A, Chopra S. Succinate dehydrogenase-deficient gastrointestinal stromal tumors. Arch Pathol Lab Med. 2020;144(5):655\u201360. https:\/\/doi.org\/10.5858\/arpa.2018-0370-RS.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"1249_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/jcp-2022-208462","volume":"77","author":"OT Giger","year":"2024","unstructured":"Giger OT, Ten Hoopen R, Shorthouse D, Abdullahi S, Bulusu VR, Jadhav S, et al. Preferential MGMT hypermethylation in SDH-deficient wild-type GIST. J Clin Pathol. 2024;77(1):34\u20139. https:\/\/doi.org\/10.1136\/jcp-2022-208462.","journal-title":"J Clin Pathol"},{"issue":"7","key":"1249_CR41","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","volume":"2","author":"SA Boikos","year":"2016","unstructured":"Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016;2(7):922. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0256.","journal-title":"JAMA Oncol"},{"issue":"7781","key":"1249_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-019-1668-3","volume":"575","author":"WA Flavahan","year":"2019","unstructured":"Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 2019;575(7781):229\u201333. https:\/\/doi.org\/10.1038\/s41586-019-1668-3.","journal-title":"Nature"},{"issue":"15","key":"1249_CR43","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2005.05.3439","volume":"24","author":"CP Raut","year":"2006","unstructured":"Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24(15):2325\u201331. https:\/\/doi.org\/10.1200\/JCO.2005.05.3439.","journal-title":"J Clin Oncol"},{"key":"1249_CR44","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211023278","volume":"13","author":"M Nannini","year":"2021","unstructured":"Nannini M, Rizzo A, Indio V, Schipani A, Astolfi A, Pantaleo MA. Targeted therapy in SDH-deficient GIST. Ther Adv Med Oncol. 2021;13:17588359211023278. https:\/\/doi.org\/10.1177\/17588359211023278.","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"1249_CR45","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/annonc\/mdw228","volume":"27","author":"E Ben-Ami","year":"2016","unstructured":"Ben-Ami E, Barysauskas CM, Von Mehren M, Heinrich MC, Corless CL, Butrynski JE, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016;27(9):1794\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdw228.","journal-title":"Ann Oncol"},{"issue":"1","key":"1249_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01832-9","volume":"22","author":"J Martin-Broto","year":"2023","unstructured":"Martin-Broto J, Valverde C, Hindi N, Vincenzi B, Martinez-Trufero J, Grignani G, et al. REGISTRI: regorafenib in first-line of KIT\/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Mol Cancer. 2023;22(1):127. https:\/\/doi.org\/10.1186\/s12943-023-01832-9.","journal-title":"Mol Cancer"},{"issue":"1","key":"1249_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/1078-0432.CCR-21-2092","volume":"28","author":"M Yebra","year":"2022","unstructured":"Yebra M, Bhargava S, Kumar A, Burgoyne AM, Tang CM, Yoon H, et al. Establishment of patient-derived succinate dehydrogenase-deficient gastrointestinal stromal tumor models for predicting therapeutic response. Clin Cancer Res. 2022;28(1):187\u2013200. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2092.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1249_CR48","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-19-1069","volume":"26","author":"M Von Mehren","year":"2020","unstructured":"Von Mehren M, George S, Heinrich MC, Schuetze SM, Yap JT, Yu JQ, et al. Linsitinib (OSI-906) for the treatment of adult and pediatric wild-type gastrointestinal stromal tumors, a SARC phase II study. Clin Cancer Res. 2020;26(8):1837\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1069.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1249_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1158\/1078-0432.CCR-22-2168","volume":"29","author":"JA Ligon","year":"2023","unstructured":"Ligon JA, Sundby RT, Wedekind MF, Arnaldez FI, Del Rivero J, Wiener L, et al. A phase II trial of guadecitabine in children and adults with SDH-deficient GIST, pheochromocytoma, paraganglioma, and HLRCC-associated renal cell carcinoma. Clin Cancer Res. 2023;29(2):341\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2168.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1249_CR50","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2159-8290.CD-13-0092","volume":"3","author":"JK Killian","year":"2013","unstructured":"Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013;3(6):648\u201357. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0092.","journal-title":"Cancer Discov"},{"key":"1249_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00504","volume":"10","author":"A Astolfi","year":"2020","unstructured":"Astolfi A, Indio V, Nannini M, Saponara M, Schipani A, De Leo A, et al. Targeted deep sequencing uncovers cryptic KIT mutations in KIT\/PDGFRA\/SDH\/RAS-P wild-type GIST. Front Oncol. 2020;10:504. https:\/\/doi.org\/10.3389\/fonc.2020.00504.","journal-title":"Front Oncol"},{"issue":"1","key":"1249_CR52","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.canlet.2011.07.029","volume":"312","author":"M Daniels","year":"2011","unstructured":"Daniels M, Lurkin I, Pauli R, Erbst\u00f6\u00dfer E, Hildebrandt U, Hellwig K, et al. Spectrum of KIT\/PDGFRA\/BRAF mutations and phosphatidylinositol-3-kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett. 2011;312(1):43\u201354. https:\/\/doi.org\/10.1016\/j.canlet.2011.07.029.","journal-title":"Cancer Lett"},{"issue":"2","key":"1249_CR53","doi-asserted-by":"publisher","first-page":"310","DOI":"10.18632\/oncotarget.864","volume":"4","author":"GS Falchook","year":"2013","unstructured":"Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 2013;4(2):310\u20135. https:\/\/doi.org\/10.18632\/oncotarget.864.","journal-title":"Oncotarget"},{"issue":"7","key":"1249_CR54","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1136\/jcp.2009.064550","volume":"62","author":"A Agaimy","year":"2009","unstructured":"Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT\/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol. 2009;62(7):613\u20136. https:\/\/doi.org\/10.1136\/jcp.2009.064550.","journal-title":"J Clin Pathol"},{"issue":"10","key":"1249_CR55","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/gcc.20589","volume":"47","author":"NP Agaram","year":"2008","unstructured":"Agaram NP, Wong GC, Guo T, Maki RG, Singer S, DeMatteo RP, et al. Novel V600E BRAF mutations in imatinib\u2010naive and imatinib\u2010resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47(10):853\u20139. https:\/\/doi.org\/10.1002\/gcc.20589.","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"1249_CR56","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1158\/1078-0432.CCR-11-2230","volume":"18","author":"C Miranda","year":"2012","unstructured":"Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2012;18(6):1769\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2230.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"1249_CR57","doi-asserted-by":"publisher","first-page":"30109","DOI":"10.18632\/oncotarget.8768","volume":"7","author":"S Rossi","year":"2016","unstructured":"Rossi S, Sbaraglia M, Dell\u2019Orto MC, Gasparotto D, Cacciatore M, Boscato E, et al. Concomitant KIT\/BRAF and PDGFRA\/BRAF mutations are rare events in gastrointestinal stromal tumors. Oncotarget. 2016;7(21):30109\u201318. https:\/\/doi.org\/10.18632\/oncotarget.8768.","journal-title":"Oncotarget"},{"key":"1249_CR58","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.humpath.2017.01.005","volume":"62","author":"S Huss","year":"2017","unstructured":"Huss S, Pasternack H, Ihle MA, Merkelbach-Bruse S, Heitk\u00f6tter B, Hartmann W, et al. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT\/PDGFRA wild-type GISTs are rare events. Hum Pathol. 2017;62:206\u201314. https:\/\/doi.org\/10.1016\/j.humpath.2017.01.005.","journal-title":"Hum Pathol"},{"issue":"2","key":"1249_CR59","doi-asserted-by":"publisher","first-page":"788","DOI":"10.21037\/jgo-23-767","volume":"15","author":"S Gowda","year":"2024","unstructured":"Gowda S, Sandow L, Heinrich MC. Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib: a case report. J Gastrointest Oncol. 2024;15(2):788\u201393. https:\/\/doi.org\/10.21037\/jgo-23-767.","journal-title":"J Gastrointest Oncol"},{"issue":"11","key":"1249_CR60","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/modpathol.2013.89","volume":"26","author":"J Lasota","year":"2013","unstructured":"Lasota J, Xi L, Coates T, Dennis R, Evbuomwan MO, Wang ZF, et al. No KRAS mutations found in gastrointestinal stromal tumors (GISTs): molecular genetic study of 514 cases. Mod Pathol. 2013;26(11):1488\u201391. https:\/\/doi.org\/10.1038\/modpathol.2013.89.","journal-title":"Mod Pathol"},{"key":"1249_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/4248128","volume":"2023","author":"D Mullen","year":"2023","unstructured":"Mullen D, Vajpeyi R, Capo-Chichi JM, Nowak K, Wong N, Chetty R. Gastrointestinal stromal tumours (GISTs) with KRAS mutation: a rare but important subset of GISTs. Case Rep Gastrointest Med. 2023;2023:1\u20136. https:\/\/doi.org\/10.1155\/2023\/4248128.","journal-title":"Case Rep Gastrointest Med"},{"issue":"3","key":"1249_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000335","volume":"3","author":"L Mavroeidis","year":"2018","unstructured":"Mavroeidis L, Metaxa-Mariatou V, Papoudou-Bai A, Lampraki AM, Kostadima L, Tsinokou I, et al. Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT\/PDGFRA genes and novel genomic alterations: results from a 20-year cohort of patients with GIST from North-Western Greece. ESMO Open. 2018;3(3):e000335. https:\/\/doi.org\/10.1136\/esmoopen-2018-000335.","journal-title":"ESMO Open"},{"issue":"3","key":"1249_CR63","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/gcc.22230","volume":"54","author":"JF Hechtman","year":"2015","unstructured":"Hechtman JF, Zehir A, Mitchell T, Borsu L, Singer S, Tap W, et al. Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. Genes Chromosomes Cancer. 2015;54(3):177\u201384. https:\/\/doi.org\/10.1002\/gcc.22230.","journal-title":"Genes Chromosomes Cancer"},{"issue":"21","key":"1249_CR64","doi-asserted-by":"publisher","first-page":"30241","DOI":"10.18632\/oncotarget.7148","volume":"7","author":"J Gao","year":"2016","unstructured":"Gao J, Li J, Li Y, Li Z, Gong J, Wu J, et al. Intratumoral KIT mutational heterogeneity and recurrent KIT\/PDGFRA mutations in KIT\/PDGFRA wild-type gastrointestinal stromal tumors. Oncotarget. 2016;7(21):30241\u20139. https:\/\/doi.org\/10.18632\/oncotarget.7148.","journal-title":"Oncotarget"},{"issue":"6","key":"1249_CR65","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00535-015-1132-6","volume":"51","author":"T Nishida","year":"2016","unstructured":"Nishida T, Tsujimoto M, Takahashi T, Hirota S, Blay JY, Wataya-Kaneda M. Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I. J Gastroenterol. 2016;51(6):571\u20138. https:\/\/doi.org\/10.1007\/s00535-015-1132-6.","journal-title":"J Gastroenterol"},{"issue":"1","key":"1249_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1075-6","volume":"14","author":"E Shi","year":"2016","unstructured":"Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, et al. FGFR1 and NTRK3 actionable alterations in \u201cwild-type\u201d gastrointestinal stromal tumors. J Transl Med. 2016;14(1):339. https:\/\/doi.org\/10.1186\/s12967-016-1075-6.","journal-title":"J Transl Med"},{"issue":"4","key":"1249_CR67","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/path.4677","volume":"238","author":"M Brenca","year":"2016","unstructured":"Brenca M, Rossi S, Polano M, Gasparotto D, Zanatta L, Racanelli D, et al. Transcriptome sequencing identifies ETV6\u2013NTRK3 as a gene fusion involved in GIST. J Pathol. 2016;238(4):543\u20139. https:\/\/doi.org\/10.1002\/path.4677.","journal-title":"J Pathol"},{"issue":"9","key":"1249_CR68","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.dld.2019.07.006","volume":"51","author":"B Landi","year":"2019","unstructured":"Landi B, Blay JY, Bonvalot S, Brasseur M, Coindre JM, Emile JF, et al. Gastrointestinal stromal tumours (GISTs): French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis. 2019;51(9):1223\u201331. https:\/\/doi.org\/10.1016\/j.dld.2019.07.006.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"1249_CR69","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1158\/1541-7786.MCR-16-0376","volume":"15","author":"MA Pantaleo","year":"2017","unstructured":"Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, et al. Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in quadruple WT GIST. Mol Cancer Res. 2017;15(5):553\u201362. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0376.","journal-title":"Mol Cancer Res"},{"issue":"9","key":"1249_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093313","volume":"21","author":"A Astolfi","year":"2020","unstructured":"Astolfi A, Pantaleo MA, Indio V, Urbini M, Nannini M. The emerging role of the FGF\/FGFR pathway in gastrointestinal stromal tumor. Int J Mol Sci. 2020;21(9):3313. https:\/\/doi.org\/10.3390\/ijms21093313.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1249_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051201","volume":"10","author":"HR Ferguson","year":"2021","unstructured":"Ferguson HR, Smith MP, Francavilla C. Fibroblast growth factor receptors (FGFRs) and noncanonical partners in cancer signaling. Cells. 2021;10(5):1201. https:\/\/doi.org\/10.3390\/cells10051201.","journal-title":"Cells"},{"issue":"1","key":"1249_CR72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/PAI.0000000000000842","volume":"29","author":"S Wang","year":"2021","unstructured":"Wang S, Sun RZ, Han Q, Wang SY, Wang EH, Liu Y. Genomic study of Chinese quadruple-negative GISTs using next-generation sequencing technology. Appl Immunohistochem Mol Morphol. 2021;29(1):34\u201341. https:\/\/doi.org\/10.1097\/PAI.0000000000000842.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"10","key":"1249_CR73","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1210\/jc.2009-1156","volume":"94","author":"JA Carney","year":"2009","unstructured":"Carney JA. Carney triad: a syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors. J Clin Endocrinol Metab. 2009;94(10):3656\u201362. https:\/\/doi.org\/10.1210\/jc.2009-1156.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1249_CR74","doi-asserted-by":"publisher","first-page":"R49","DOI":"10.1530\/ERC-17-0329","volume":"25","author":"P Gopie","year":"2018","unstructured":"Gopie P, Mei L, Faber AC, Grossman SR, Smith SC, Boikos SA. Classification of gastrointestinal stromal tumor syndromes. Endocr Relat Cancer. 2018;25(2):R49-58. https:\/\/doi.org\/10.1530\/ERC-17-0329.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"1249_CR75","doi-asserted-by":"publisher","DOI":"10.3171\/2009.11.FOCUS09221","volume":"28","author":"ON Gottfried","year":"2010","unstructured":"Gottfried ON, Viskochil DH, Couldwell WT. Neurofibromatosis type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neurosurg Focus. 2010;28(1):E8. https:\/\/doi.org\/10.3171\/2009.11.FOCUS09221.","journal-title":"Neurosurg Focus"},{"issue":"7","key":"1249_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071787","volume":"14","author":"TT Liu","year":"2022","unstructured":"Liu TT, Li CF, Tan KT, Jan YH, Lee PH, Huang CH, et al. Characterization of aberrations in DNA damage repair pathways in gastrointestinal stromal tumors: the clinicopathologic relevance of \u03b3H2AX and 53BP1 in correlation with heterozygous deletions of CHEK2, BRCA2, and RB1. Cancers (Basel). 2022;14(7):1787. https:\/\/doi.org\/10.3390\/cancers14071787.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1249_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70669","volume":"14","author":"V Florou","year":"2025","unstructured":"Florou V, Jacobs MF, Casey R, Evans D, Owens B, Raygada M, et al. A review of genomic testing and SDH-deficiency in gastrointestinal stromal tumors: getting to the GIST. Cancer Med. 2025;14(3):e70669. https:\/\/doi.org\/10.1002\/cam4.70669.","journal-title":"Cancer Med"},{"issue":"1","key":"1249_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-020-0926-x","volume":"15","author":"J Fan","year":"2020","unstructured":"Fan J, Yang M, Huang B, Wang Z, Luo D, Zhang J, et al. ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation: a case report. Diagn Pathol. 2020;15(1):8. https:\/\/doi.org\/10.1186\/s13000-020-0926-x.","journal-title":"Diagn Pathol"},{"key":"1249_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.680609","volume":"12","author":"G Pitsava","year":"2021","unstructured":"Pitsava G, Settas N, Faucz FR, Stratakis CA. Carney triad, Carney-Stratakis syndrome, 3PAS and other tumors due to SDH deficiency. Front Endocrinol. 2021;12:680609. https:\/\/doi.org\/10.3389\/fendo.2021.680609.","journal-title":"Front Endocrinol"},{"issue":"4","key":"1249_CR80","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/ced.13757","volume":"44","author":"GN Wali","year":"2019","unstructured":"Wali GN, Halliday D, Dua J, Ieremia E, McPherson T, Matin RN. Cutaneous hyperpigmentation and familial gastrointestinal stromal tumour associated with KIT mutation. Clin Exp Dermatol. 2019;44(4):418\u201321. https:\/\/doi.org\/10.1111\/ced.13757.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1249_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-016-0120-8","volume":"6","author":"H Ke","year":"2016","unstructured":"Ke H, Kazi JU, Zhao H, Sun J. Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis. Cell Biosci. 2016;6(1):55. https:\/\/doi.org\/10.1186\/s13578-016-0120-8.","journal-title":"Cell Biosci"},{"key":"1249_CR82","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.humpath.2018.02.014","volume":"76","author":"PN Manley","year":"2018","unstructured":"Manley PN, Abu-Abed S, Kirsch R, Hawrysh A, Perrier N, Feilotter H, et al. Familial PDGFRA-mutation syndrome: somatic and gastrointestinal phenotype. Hum Pathol. 2018;76:52\u20137. https:\/\/doi.org\/10.1016\/j.humpath.2018.02.014.","journal-title":"Hum Pathol"},{"issue":"1","key":"1249_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s13053-016-0055-4","volume":"14","author":"R Ricci","year":"2016","unstructured":"Ricci R. Syndromic gastrointestinal stromal tumors. Hered Cancer Clin Pract. 2016;14(1):15. https:\/\/doi.org\/10.1186\/s13053-016-0055-4.","journal-title":"Hered Cancer Clin Pract"},{"issue":"10","key":"1249_CR84","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.12998\/wjcc.v11.i10.2336","volume":"11","author":"MQ Yao","year":"2023","unstructured":"Yao MQ, Jiang YP, Yi BH, Yang Y, Sun DZ, Fan JX. Neurofibromatosis type 1 with multiple gastrointestinal stromal tumors: a case report. World J Clin Cases. 2023;11(10):2336\u201342. https:\/\/doi.org\/10.12998\/wjcc.v11.i10.2336.","journal-title":"World J Clin Cases"},{"key":"1249_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2023.107992","volume":"105","author":"T Girma","year":"2023","unstructured":"Girma T, Nureta TH, Abebe DM. Unusual presentation of GIST associated with type 1 neurofibromatosis: a case report. Int J Surg Case Rep. 2023;105:107992. https:\/\/doi.org\/10.1016\/j.ijscr.2023.107992.","journal-title":"Int J Surg Case Rep"},{"key":"1249_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/398570","volume":"2013","author":"PF Salvi","year":"2013","unstructured":"Salvi PF, Lorenzon L, Caterino S, Antolino L, Antonelli MS, Balducci G. Gastrointestinal stromal tumors associated with neurofibromatosis 1: a single centre experience and systematic review of the literature including 252 cases. Int J Surg Oncol. 2013;2013:1\u20138. https:\/\/doi.org\/10.1155\/2013\/398570.","journal-title":"Int J Surg Oncol"},{"issue":"9","key":"1249_CR87","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1097\/01.pas.0000159775.77912.15","volume":"29","author":"J Andersson","year":"2005","unstructured":"Andersson J, Sihto H, Meis-Kindblom JM, Joensuu H, Nupponen N, Kindblom LG. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol. 2005;29(9):1170\u20136. https:\/\/doi.org\/10.1097\/01.pas.0000159775.77912.15.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"1249_CR88","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s10637-009-9306-9","volume":"28","author":"K Shirao","year":"2010","unstructured":"Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, et al. Phase I\/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs. 2010;28(6):866\u201375. https:\/\/doi.org\/10.1007\/s10637-009-9306-9.","journal-title":"Invest New Drugs"},{"issue":"14","key":"1249_CR89","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-08-0086","volume":"14","author":"C Mussi","year":"2008","unstructured":"Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res. 2008;14(14):4550\u20135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0086.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1249_CR90","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.2169\/internalmedicine.2321-18","volume":"58","author":"A Fujimi","year":"2019","unstructured":"Fujimi A, Nagamachi Y, Yamauchi N, Tamura F, Kimura T, Miyajima N, et al. Gastrointestinal stromal tumor in a patient with neurofibromatosis type 1 that was successfully treated with regorafenib. Intern Med. 2019;58(13):1865\u201370. https:\/\/doi.org\/10.2169\/internalmedicine.2321-18.","journal-title":"Intern Med"},{"issue":"1","key":"1249_CR91","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.ejhg.5201904","volume":"16","author":"B Pasini","year":"2008","unstructured":"Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet. 2008;16(1):79\u201388. https:\/\/doi.org\/10.1038\/sj.ejhg.5201904.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"1249_CR92","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2796.2009.02110.x","volume":"266","author":"CA Stratakis","year":"2009","unstructured":"Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med. 2009;266(1):43\u201352. https:\/\/doi.org\/10.1111\/j.1365-2796.2009.02110.x.","journal-title":"J Intern Med"},{"issue":"1","key":"1249_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-2-16","volume":"2","author":"MA Postow","year":"2012","unstructured":"Postow MA, Robson ME. Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. Clin Sarcoma Res. 2012;2(1):16. https:\/\/doi.org\/10.1186\/2045-3329-2-16.","journal-title":"Clin Sarcoma Res"},{"issue":"12","key":"1249_CR94","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc3143","volume":"11","author":"CL Corless","year":"2011","unstructured":"Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11(12):865\u201378. https:\/\/doi.org\/10.1038\/nrc3143.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1249_CR95","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","volume":"33","author":"PG Casali","year":"2022","unstructured":"Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Gastrointestinal stromal tumours: ESMO\u2013EURACAN\u2013GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.005.","journal-title":"Ann Oncol"},{"issue":"1","key":"1249_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-024-02672-0","volume":"132","author":"I Judson","year":"2025","unstructured":"Judson I, Jones RL, Wong NACS, Dileo P, Bulusu R, Smith M, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines. Br J Cancer. 2025;132(1):1\u201310. https:\/\/doi.org\/10.1038\/s41416-024-02672-0.","journal-title":"Br J Cancer"},{"issue":"1","key":"1249_CR97","first-page":"1","volume":"6","author":"P Rutkowski","year":"2020","unstructured":"Rutkowski P, Prochorec-Sobieszek M, W\u0105grodzki M, Seliga K, Krzakowski M, Czarnecka AM, et al. Diagnostyka z Wykorzystaniem Sekwencjonowania Nast\u0119pnej Generacji (NGS) w Mi\u0119sakach: Rekomendacje. Onkologia w Praktyce Klinicznej - Edukacja. 2020;6(1):1\u20138.","journal-title":"Onkologia w Praktyce Klinicznej - Edukacja."},{"issue":"6","key":"1249_CR98","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10147-024-02488-1","volume":"29","author":"S Hirota","year":"2022","unstructured":"Hirota S, Tateishi U, Nakamoto Y, Yamamoto H, Sakurai S, Kikuchi H, et al. English version of Japanese clinical practice guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology. Int J Clin Oncol. 2022;29(6):647\u201380. https:\/\/doi.org\/10.1007\/s10147-024-02488-1.","journal-title":"Int J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01249-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01249-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01249-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:51:55Z","timestamp":1790916715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01249-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1249"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01249-6","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anna Klimczak has received honoraria for lectures and advisory boards from Bristol-Myers Squibb, Philogen, Amgen, Cogent, and Genesis Pharma. Katarzyna Kisielewska has received honoraria for lectures, manuscript writing, and educational events from BMS, MSD, Pierre Fabre, and Medison Pharma and travel grants from MSD, Genesis Pharma, and Pierre Fabre. Anna Szumera-Cie\u0107kiewicz has no conflicts of interest that are directly relevant to the content of this article. Piotr Rutkowski has received honoraria for lectures and advisory boards from Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Philogen, Immunome, Cogent, Genesis Pharma, and Medison Pharma and is a member of IDMC for Erasca.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based exclusively on previously published studies and does not contain any new studies involving human participants or animals performed by any of the authors. Therefore, ethics approval was not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current study.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AK: conceptualization, literature review, writing (original draft). KK: writing (review and editing), preparation of figures and tables. AS-C: conceptualization, review, supervision. PR: conceptualization, review, supervision.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}